New ALS Treatment, AMX0035, Lacks Evidence of Benefit, FDA Panel Finds With a 6-4 vote, the group of independent advisers to [...] By digitalstudios|2022-03-30T22:45:15+00:00March 30, 2022|3rd Party Pharmaceutical Industry News|Comments Off on New ALS Treatment, AMX0035, Lacks Evidence of Benefit, FDA Panel Finds Read More
